Because of a preconceived notion that eliminating reactive metabolite (RM) formation with
new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM …

The diagnosis of drug-induced liver injury (DILI) is a challenging problem, often confounded
by incomplete clinical information and the difficulty of eliciting exposure to herbal products …

Amiodarone is an iodinated benzofuran derivative, a highly lipophilic drug with
unpredictable pharmacokinetics. Although originally classified as a class III agent due to its …

In addition to the usual associations with insulin resistance, type 2 diabetes, central obesity,
and hypertriglyceridemia, nonalcoholic steatohepatitis (NASH) has been associated with …

Cholestatic drug‐induced liver injury (DILI) can be a diagnostic challenge due to a large
differential diagnosis, variability in clinical presentation, and lack of serologic biomarkers …

Featuring more than 4100 references, Drug-Induced Liver Disease is an invaluable
reference for gastroenterologists, hepatologists, family physicians, internists, pathologists …

Background Nonalcoholic fatty disease (NAFLD) is the most common liver disease, since it
is strongly associated with obesity and metabolic syndrome pandemics. NAFLD may affect …

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of liver disease in developed
countries. Its frequency is increasing in the general population mostly due to the widespread …

Hepatic steatosis is defined as fat deposition within hepatocytes (Fig. 1). It is seen
microscopically as vacuoles in a microvesicular or macrovesicular distribution …

Drugs may cause several overlapping syndromes of cholestasis, the pathophysiological
syndrome resulting from impaired bile flow. These reactions comprise approximately 17% of …